medigraphic.com
Instituto Nacional de Salud Pública

2023, Number 4

<< Back Next >>

salud publica mex 2023; 65 (4)

SARS-CoV-2 seroprevalence and respiratory disease disability claims in Mexico City Metropolitan Area

Barros-Sierra D, Zepeda-Tello R, Tamayo-Ortiz M, Gutiérrez-Díaz HO, Pérez-Chávez VA, Rosa-Parra JA, Nieto-Barajas LE, Méndez-Aranda M, Herrera-Montalvo LA, Hernández-Ávila M

Language: English
References: 37
Page: 334-343
PDF size: 360.31 Kb.


ABSTRACT

Objective. To characterize the impact of SARS-CoV-2 infection in workers from an essential large-scale company in the Greater Mexico City Metropolitan Area using point prevalence of acute infection, point prevalence of past infection through serum antibodies and respiratory disease short-term disability claims (RD-STDC). Materials and methods. Four randomized surveys, three during 2020 before and one after (December 2021) vaccines’ availability. Outcomes: point prevalence of acute infection through saliva PCR (polymerase chain reaction) testing, point prevalence of past infection through serum antibodies against Covid-19, RD-STDC and prevalence of symptoms during the previous six months. Results. Prevalence of SARS-CoV-2 cases was 1.29-4.88%, on average, a quarter of participants pre-vaccination were seropositive; over half of participants with a RD-STDC had antibodies. The odds of having antibodies were 6-7 times more among workers with an RD-STDC. Conclusions. High antibody levels against Covid-19 in this study population reflects that coverage is high among workers in this industry. STDCs are a useful tool to track workplace epidemics.


REFERENCES

  1. Carlsten C, Gulati M, Hines S, Rose C, Scott K, Tarlo SM, et al. COVID-19 as an occupational disease. Am J Ind Med. 2021;64(4):227-37.https://doi.org/10.1002/ajim.23222

  2. Grupo Técnico Asesor de Vacunación Covid-19. Priorización inicial yconsecutiva para la vacunación contra SARS-CoV-2 en la población mexicana.Recomendaciones preliminares. Salud Publica Mex. 2021;63(2):288-309. https://doi.org/10.21149/12399

  3. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al.Model-informed COVID-19 vaccine prioritization strategies by age andserostatus. Science. 2021;371(6532):916-21. https://doi.org/10.1126/science.abe6959

  4. Barrientos-Gutiérrez T, Alpuche-Aranda CM, Bautista-Arredondo S. Respuestaa “Reflexiones sobre la estrategia de vacunación en México parapersonas de 50 a 59 años”. Salud Publica Mex. 2021;63(5):596-7. https://doi.org/10.21149/12815

  5. Knaul FM, Touchton M, Arreola-Ornelas H, Atun R, Anyosa-Calderón RJ,Frenk J, et al. Punt politics as failure of health system stewardship: evidencefrom the COVID-19 pandemic response in Brazil and Mexico. Lancet RegHealth Am. 2021;4:100086. https://doi.org/10.1016/j.lana.2021.100086

  6. Gómez-Dantés O, Sesma S, Becerril VM, Knaul FM, Arreola H, Frenk J.Sistema de salud de México. Salud Publica Mex. 2011;53(suppl2):s220-32[cited March 15, 2023]. Available from: https://saludpublica.mx/index.php/spm/article/view/5043

  7. Gobierno de México. Lineamientos Técnicos de Seguridad Sanitaria enel Entorno Laboral. Entornos Laborales Seguros y Saludables [Internet][cited March 15, 2023]. Available from: https://nuevanormalidad.gob.mx/

  8. Hernández-Avila M, Tamayo-Ortiz M, Vieyra-Romero W, Gutiérrez-DíazH, Zepeda-Tello R, Barros-Sierra D, et al. Use of private sector workforcerespiratory disease short-term disability claims to assess SARSCoV-2, Mexico, 2020. Emerg Infect Dis. 2022;28(1):214-18. https://doi.org/10.3201/eid2801.211357

  9. Hernández-Ávila M, Vieyra-Romero W, Gutiérrez-Díaz H, Barros-SierraD, Zepeda R, Segura-Sánchez C, et al. Comportamiento epidemiológicode SARS-CoV-2 en población trabajadora afiliada al Instituto Mexicanodel Seguro Social. Salud Publica Mex. 2021;63(5):607-18. https://doi.org/10.21149/12495

  10. Sjörs Dahlman A, Anund A. Seroprevalence of SARS-CoV-2 antibodiesamong public transport workers in Sweden. J Transp Health.2022;27:101508. https://doi.org/10.1016/j.jth.2022.101508

  11. Gashi B, Osmani V, Halili R, Hoxha T, Kamberi A, Hoti N, et al.Seroprevalence of Anti-SARS-CoV-2 Antibodies among MunicipalStaff in the Municipality of Prishtina. Int J Environ Res Public Health.2021;18(23):12545. https://doi.org/10.3390/ijerph182312545

  12. Vachon MS, Demmer RT, Yendell S, Draeger KJ, Beebe TJ, Hedberg CW.SARS-CoV-2 Seroprevalence survey in grocery store workers-Minnesota,2020-2021. Int J Environ Res Public Health. 2022;19(6):3501. https://doi.org/10.3390/ijerph19063501

  13. Särndal CE, Swensson B, Wretman J. Model Assisted Survey Sampling.Springer Science & Business Media;2013:716.

  14. Abbott. ARCHITECT ci4100 Integrated System | Core Laboratoryat Abbott [Internet]. USA: 2023 [cited March 15, 2023]. Available from:https://www.corelaboratory.abbott/int/en/offerings/brands/architect/architect-ci4100.html

  15. Abbott. AdviseDx SARS-CoV-2 IgG II [Internet]. Ireland: 2022 [citedMarch 15, 2023]. Available from: https://www.fda.gov/media/146371/download

  16. Roche. Elecsys Anti-SARS-CoV-2 Scobas [Internet]. USA: 2022 [citedMarch 15, 2023]. Available from: https://www.fda.gov/media/144037/download

  17. Thermo Fisher Scientific Inc. TaqPath COVID-19 CE-IVD RT-PCRKit instructions for use [Internet]. USA: 2020 [cited March 15, 2023].Available from: https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0019215_TaqPathCOVID-19_CE-IVD_RT-PCR%20Kit_IFU.pdf

  18. Zepeda R. SARSCOV2-seroprevalence-paper-essential-workers [Internet]ci. github: 2023 [cited March 15, 2023]. Available from: https://github.com/RodrigoZepeda/SARSCOV2-seroprevalence-paper-essential-workers

  19. Gelman A, Carpenter B. Bayesian analysis of tests with unknownspecificity and sensitivity. J R Stat Soc Ser C Appl Stat. 2020;69(5):1269-83.https://doi.org/10.1111/rssc.12435

  20. Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, et al.COVID-19 antibody seroprevalence in Santa Clara County, California. Int JEpidemiol. 2021;50(2):410-19. https://doi.org/10.1093/ije/dyab010

  21. Betancourt MJ, Girolami M. Hamiltonian Monte Carlo for HierarchicalModels [internet]. arXiv stat. 2013. https://doi.org/10.48550/arXiv.1312.0906

  22. R Interface to CmdStan [Internet] [cited June 30, 2022]. Available from:https://mc-stan.org/cmdstanr/

  23. Stan [Internet]. stan-dev.github.io [cited June 30, 2022]. Available from:https://mc-stan.org/

  24. European Environment Agency. R Core Team (2020) [Internet]. Vienna,Austria: 2020 [cited June 30, 2022]. Available from: https://www.eea.europa.eu/data-and-maps/indicators/oxygen-consuming-substances-inrivers/r-development-core-team-2006

  25. Barros-Sierra D, Zepeda-Tello R, Tamayo-Ortiz M, Gutiérrez-Diaz H,Pérez-Chávez V, Rosa-Parra JA, et al. Supplementary material_SPM_SARSCoV-2 seroprevalence and respiratory disease disability claims in MexicoCity Metropolitan Area [cited july 14, 2023]. Available from: https://figshare.com/articles/journal_contribution/Supplementary_material_SPM_2023_docx/23681397/1

  26. Secretaría de Salud. SANA DISTANCIA COVID-19 [Internet]. México:2020 [cited March 15, 2023]. Available from: https://www.gob.mx/salud/documentos/sana-distancia

  27. Sánchez-Pájaro A, Pérez-Ferrer C, Basto-Abreu A, Rivera-Dommarco J,Barquera S, Denova-Gutiérrez E, et al. Seroprevalencia de SARS-CoV-2 enadultos y adultos mayores en México y su asociación con enfermedadescrónicas. Ensanut 2020 Covid-19. Salud Publica Mex. 2021;63(6):705-12.https://doi.org/10.21149/13163

  28. CSSEGISandData. COVID-19 Data Repository by the Center forSystems Science and Engineering (CSSE) at Johns Hopkins University[Internet]. github: 2022 [cited June 30, 2022]. Available from: https://github.com/CSSEGISandData/COVID-19

  29. Quigley DD, Qureshi N, Gahlon G, Gidengil C. Worker and employerexperiences with COVID-19 and the California Workers’ CompensationSystem: A review of the literature. Am J Ind Med. 2022;65(3):203-13.https://doi.org/10.1002/ajim.23326

  30. Dyal JW, Grant MP, Broadwater K, Bjork A, Waltenburg MA, Gibbins JD,et al. COVID-19 among workers in meat and poultry processing facilities -19 States, April 2020. MMWR Morb Mortal Wkly Rep. 2020;69(18):557-61.http://doi.org/10.15585/mmwr.mm6918e3

  31. Groenewold MR, Burrer SL, Ahmed F, Uzicanin A, Free H, LuckhauptSE. Increases in health-related workplace absenteeism among workers inessential critical infrastructure occupations during the COVID-19 pandemic- United States, March-April 2020. MMWR Morb Mortal Wkly Rep.2020;69(27):853-8. http://doi.org/10.15585/mmwr.mm6927a1

  32. Mendola M, Tonelli F, Garletti FS, Greco D, Fiscella M, Cucchi I, et al.COVID-19 impact and vaccine effectiveness among healthcare workers ofa large University Hospital in Lombardy, Italy. Med Lav. 2021;112(6):453-64. https://doi.org/10.23749/mdl.v112i6.11983

  33. Choudhry N, Drysdale K, Usai C, Leighton D, Sonagara V, Buchanan R,et al. Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in healthcareworkers in East London, UK. Front Med. 2021;8:642723. https://doi.org/10.3389/fmed.2021.642723

  34. Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C,Sonntagbauer M, et al. Antibody response to SARS-CoV-2 for more thanone year − kinetics and persistence of detection are predominantly determinedby avidity progression and test design. J Clin Virol. 2022;146:105052.https://doi.org/10.1016/j.jcv.2021.105052

  35. Ambrosino I, Barbagelata E, Ortona E, Ruggieri A, Massiah G, GiannicoOV, et al. Gender differences in patients with COVID-19: a narrativereview. Monaldi Arch Chest Dis. 2020;90(2). https://doi.org/10.4081/monaldi.2020.1389

  36. Instituto Nacional de Estadística y Geografía. Resultados de la encuestanacional de ocupación y empleo. Nueva edición (ENOEN) Cifrasdurante el cuarto trimestre de 2020 [Internet]. México: Inegi, 2020 [citedMarch 15, 2023]. Available from: https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2021/enoe_ie/enoe_ie2021_02.pdf

  37. Mukherjee S, Pahan K. Is COVID-19 Gender-sensitive? J NeuroimmunePharmacol. 2021;16(1):38-47. https://doi.org/10.1007/s11481-020-09974-z




2020     |     www.medigraphic.com